{
    "clinical_study": {
        "@rank": "116018", 
        "arm_group": {
            "arm_group_label": "Systemic sclerosis patients", 
            "arm_group_type": "Other", 
            "description": "Systemic sclerosis patients will have blood tested for fibrotic enzyme levels"
        }, 
        "brief_summary": {
            "textblock": "The aim of our study is to find a biomarker for fibrosis or vasculopathy in systemic\n      sclerosis. We will evaluate a possible correlation between semaphorin 7a, semaphorin 3a and\n      lysyl oxidase and  fibrosis (lung and skin) or vasculopathy in patients with systemic\n      sclerosis. The results obtained may help us diagnose these complications of systemic\n      sclerosis and hopefully even monitor patient treatment."
        }, 
        "brief_title": "Lysyl Oxidase, Semaphorin 7a and Semaphorin 3a in Patients With Systemic Sclerosis", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Systemic Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Scleroderma, Systemic", 
                "Scleroderma, Diffuse", 
                "Sclerosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Systemic Sclerosis Patients\n\n          -  Written consent to participation in study\n\n        Exclusion Criteria:\n\n          -  Serious active medical condition\n\n          -  Other autoimmune rheumatic disease\n\n          -  Current or past allergic/inflammatory reaction\n\n          -  Liver disease\n\n          -  Pregnant or breastfeeding\n\n          -  Illegal drug or alcohol abuse"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01943968", 
            "org_study_id": "HYMC-075-13"
        }, 
        "intervention": {
            "arm_group_label": "Systemic sclerosis patients", 
            "intervention_name": "Blood test", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Haifa", 
                    "country": "Israel"
                }, 
                "name": "Bnai Zion Medical Center"
            }, 
            "investigator": {
                "last_name": "Karina Zilber, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "1", 
        "overall_contact": {
            "email": "karinazilber@gmail.com", 
            "last_name": "Karina Zilber, MD", 
            "phone": "972-54-7870716"
        }, 
        "overall_official": {
            "affiliation": "Bnai Zion Medical Center", 
            "last_name": "Doron River, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will undergo blood tests before study and after six months to determine  levels of lysyl oxidase, semaphorin 7a and 3a and thus determine severity of the disease (systemic sclerosis).", 
            "measure": "Fibrin Enzyme Levels in Blood", 
            "safety_issue": "No", 
            "time_frame": "Six months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01943968"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Hillel Yaffe Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hillel Yaffe Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}